Omid Hamid, MD

NP Schollenberger addresses the particularly challenging and understudied population of immunocompromised patients with advanced CSCC.

Both panelists describe multidisciplinary care coordination models.

Dr. Hamid presents an 86-year-old retired construction worker with diabetes, hypertension, and prior basal cell carcinoma, now with a 2.8 cm facial CSCC lesion and imaging-confirmed pulmonary metastases.

Dr. Zeitouni compares immune-mediated adverse event rates across checkpoint inhibitor agents in advanced CSCC.

Dr. Hamid presents a 71-year-old male smoker with coronary artery disease and a 3.5 cm cervical CSCC lesion that has recurred after multiple surgical resections and adjuvant radiation therapy.

NP Schollenberger addresses how she interprets and communicates efficacy data to patients.

Experts unpack advanced cutaneous squamous cell carcinoma risks, comorbidities, and PD-1/PD-L1 immunotherapy strategies for unresectable disease.

Experts unpack unresectable cutaneous squamous cell carcinoma, weighing PD-1/PD-L1 immunotherapy benefits and risks in older, comorbid patients.

When pembrolizumab is combined with immunotherapies, the incidence of grade 3 to 5 toxicities increases, especially with anti–CTLA-4 combinations.

“We’ve seen with the initial anti-CTLA-4 ipilimumab experience that, as time went by, we were better at identifying and managing toxicities,” stated Omid Hamad, MD.

A pooled analysis found pembrolizumab has a discontinuation rate of 12.7%, and a major key to handling it is maintaining good communication between the doctor and the patient.

Omid Hamid, MD, gives his perspective on the use of tumor-infiltrating lymphocyte therapy for patients with melanoma.

There has never been a referendum on IL-2. True, in the era of paradigm-shifting therapies, IL-2 may be overlooked at times, but it must not be excluded from the conversation.